Ra Medical Systems Osake

Ra Medical Systems PEG

Delisted

PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä Ra Medical Systems (RMED) 22.8.2026 päivämäärällä on −0,00. Edellisenä vuonna PEG-suhde (Hinta-tuotto-kasvu-suhde) oli −0,00 — muutos −17,95 % (korkeampi).

PEG

−0,00

YoY

−17,95%

Viimeksi päivitetty:

PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä Ra Medical Systems on 2026 −0,00 . PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä Ra Medical Systems oli 2025 −0,00 . Se laskee −17,95% korkeampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Ra Medical Systems Osakeanalyysi

Mitä Ra Medical Systems tekee? Ra Medical Systems Inc. is a California-based company specializing in the development and sale of medical devices for the treatment of vascular diseases. The company was founded in 2002 and is headquartered in Carlsbad. The company was founded by Dr. Dean Irwin and Dr. Melissa Burstein, both experts in laser therapy. The company initially focused on developing laser systems for the treatment of skin diseases. In 2016, the company changed its business strategy and shifted its focus to the development of medical devices for the treatment of vascular diseases. Since then, the company has become a leading provider of devices for the treatment of peripheral artery occlusive disease (PAOD) and other vascular diseases. The business model of Ra Medical Systems Inc. is based on selling high-tech medical devices and their corresponding accessories. The company sells its products directly to medical facilities and healthcare providers in the US and some international markets. The company also provides training, technical support, and service to ensure the safe and effective use of its products. Ra Medical Systems Inc. offers two main products: the DABRA™ System and the Pharos™ System. Both systems use pulsed laser therapy for the treatment of vascular diseases. The DABRA™ System is a laser system specifically designed for the treatment of peripheral artery occlusive disease (PAOD). It is the only FDA-approved system that offers atherectomy laser therapy. The system enables fast and safe treatment of blocked arteries and is less invasive than traditional surgical procedures. The DABRA™ System also has the potential to reduce the need for long-term medication and repeated procedures, which can lower treatment costs. The Pharos™ System is a laser system specifically designed for the treatment of skin diseases such as psoriasis, vitiligo, and atopic dermatitis. The system uses a high-energy dose to selectively destroy abnormal functioning tissue without affecting surrounding tissue. The Pharos™ System has the potential to improve the quality of life for patients with skin diseases and expand therapeutic options for this patient group. Ra Medical Systems Inc. also offers a complete accessory catalog for its products, including catheters and accessories for the DABRA™ System and handpieces and cooling devices for the Pharos™ System. In conclusion, Ra Medical Systems Inc. is a leading provider of medical devices for the treatment of vascular diseases and skin diseases. The company specializes in the development of high-tech laser systems that provide safe and effective procedures for patients and doctors. The DABRA™ System is a revolutionary laser system for the treatment of PAOD that has the potential to reduce the need for invasive surgical procedures and long-term medication. The Pharos™ System expands therapeutic options for patients with skin diseases and has the potential to improve the quality of life for this patient group. Ra Medical Systems on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Ra Medical Systems osakkeesta

Yhtiön Ra Medical Systems PEG-suhde (Hinta-tuotto-kasvu-suhde) on −0,00 vuonna 2026.

PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä Ra Medical Systems muuttui arvosta −0,00 arvoon −0,00, mikä edustaa −17,95 % muutosta. Arvo on korkeampi kuin edellisenä vuonna.

Eurpoolissa voit löytää PEG-suhde (Hinta-tuotto-kasvu-suhde) Ra Medical Systems:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

PEG-suhde korjaa P/E-suhteen odotetulla tuottojen kasvuvauhdilla. PEG alle 1 voi viitata osakkeeseen, joka on aliarvostettu suhteessa sen kasvupotentiaaliin.

PEG = P/E-suhde / Odotettu vuosittainen EPS-kasvuprosentti

Arvioidakseen PEG-suhde (Hinta-tuotto-kasvu-suhde):n, on olennaista verrata sitä saman alan ja sektorin kilpailijoihin. Eulerpoolissa voit löytää suoria alan vertailuja PEG-suhde (Hinta-tuotto-kasvu-suhde):lle.

"Hyvä" vaihtelee alan ja yrityksen kehitysvaiheen mukaan. Eulerpoolissa voit verrata PEG-suhde (Hinta-tuotto-kasvu-suhde):n Ra Medical Systems alan vertaisiin ja alan keskiarvoon arvioidaksesi houkuttelevuuden.

Access this data via the Eulerpool API

Arvostus — Ra Medical Systems

Kaikki tunnusluvut — Ra Medical Systems